VITUZ
Peakchlorpheniramine maleate; hydrocodone bitartrate
NDAORALSOLUTION
Approved
Feb 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VITUZ is a fixed-dose oral solution combining chlorpheniramine maleate (first-generation antihistamine) and hydrocodone bitartrate (opioid analgesic/antitussive). It is indicated for symptomatic relief of cough and upper respiratory symptoms in patients requiring both antihistamine and opioid antitussive action. The combination leverages antihistamine sedation and opioid cough suppression for multi-symptom cold/allergy relief.
Peak
Product is in peak commercial phase with moderate competitive intensity (30% pressure), suggesting established market presence but active defense required from brand teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VITUZ positions you in a mature, peak-stage product with stable but non-growth commercial dynamics and minimal linked job postings. Career progression depends on operational excellence, market defense against generics/competitors, and cross-functional cost management rather than product innovation or clinical expansion.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.